Lower extremity peripheral arterial disease (PAD) is prevalent in the Medicare population and is associated with high rates of myocardial infarction, stroke, amputation, and death. Nevertheless, national health expenditures for PAD are not known. We hypothesized that PAD-related costs are high, increase with age, and that treatment rates would be less than known PAD prevalence. The objective was to determine national health care expenditures for PAD in the United States. PADrelated treatment costs were calculated in the elderly, non-disabled Medicare population. The cost analysis relied on the 5% control population for the linked SEER-Medicare data and Medicare claims for the calendar year 2001, identifying PAD cases based on diagnosis and procedure codes. Costs were aggregated separately for inpatient and outpatient treatment and estimates adjusted to reflect the Medicare population. A total of $4.37 billion was spent on PAD-related treatment and 88% of expenditures were for inpatient care. Medicare program outlays totaled $3.87 billion, while enrollees (or their supplemental insurance) spent the remaining $500 million. In total, 6.8% of the elderly Medicare population received treatment for PAD. Treatment increased with age at rates of 4.5%, 7.5%, and 11.8% for individuals aged 65-74, 75-84, and >85 years, respectively. PAD-related costs accounted for approximately 13% of all Medicare Part A and B expenditures for the PAD-treated cohort, and 2.3% of total Medicare Part A and B expenditures. In conclusion, US national PAD-related costs are high, associated with inpatient care, and increase with age. PAD is treated at rates lower than the known PAD prevalence as only approximately one-third of the population with known PAD had detectable PAD-related health care costs in our analysis. The potential impact of earlier PAD detection and use of outpatient preventive strategies on total national PAD health care costs is unknown.
Introduction
Lower extremity peripheral arterial disease (PAD) is a highly prevalent atherosclerotic syndrome; the direct health care consequences are known to be potentially expensive, and contribute to national health care costs. 1, 2 Lower extremity PAD now affects between 8 and 10 million Americans and its prevalence will likely increase as the population ages. PAD impairs quality of life, is the primary cause of limb amputation, and individuals with PAD suffer high rates of myocardial infarction, stroke, amputation, and death. [3] [4] [5] The burden of PAD falls primarily on the elderly, as it is prevalent in 12-15% of those aged over 65 years and this prevalence is high in individuals with diabetes. [5] [6] [7] [8] While the consequences of PAD are potentially severe, current treatments for PAD can improve quality of life and decrease these adverse health outcomes. 1, 5, 9 Risk factors for PAD include diabetes, hypertension, high cholesterol, smoking, and obesity, and their treatment could both diminish incident PAD and lower rates of progression and ischemic events. 5, 10 Despite its prevalence, the Medicare expenditures for PAD have not previously been calculated. Evaluation of the economic impact of PAD is important for assessing the cost-effectiveness of preventive, medical, endovascular, surgical, and rehabilitative interventions.
Methods

Data source
We used the 2001 5% non-cancer Surveillance, Epidemiology, and End Results (SEER) data, which includes Medicare enrollment records and utilization data, to estimate the annual cost of PAD. SEER, a population-based cancer registry sponsored by the National Cancer Institute, collects information on cancer incidence and survival from 11 population-based cancer registries; these 11 registries include about 14% of the US population. The individuals in the 5% non-cancer file were identified from a random sample of Medicare beneficiaries residing in the SEER areas. The SEER data are affordable and population-based, and hence a good source of information for this analysis. While SEER-Medicare was created as a cancer database, the control population is derived from the larger Medicare database and thus remains representative of the full national Medicare population of elderly individuals with no history of cancer. Since PAD is particularly prevalent in the elderly (and 98% of all US citizens over the age of 65 have health insurance coverage through Medicare), Medicare claims will reflect a large portion of PAD costs. We restricted our analysis to elderly, fee-for-service beneficiaries.
Because our study used pre-existing data with no personal identifiers, the Human Subjects Committee of the University of Minnesota's Institutional Review Board determined that it was exempt from review.
Identification of PAD cases
For this study, we defined 'PAD' as arterial disease of the infra-renal aorta and lower extremities, exclusive of arterial disease of the carotid arteries, upper extremities, descending and abdominal aorta, and other first order aortic branches. Current coding standards are less distinct for PAD-related illness and treatment than for most other cardiovascular diseases. We developed an algorithm that more precisely defined cases and assessed PAD health care costs that occurred in both inpatient and outpatient settings. This algorithm expands upon the definition used by Margolis, et al. in 2005 and uses separate definitions for inpatient and outpatient care. 11 The inpatient definition requires both a PAD-related diagnosis code as the first or second discharge diagnosis and for the discharge to be categorized as a PAD-specific diagnosis-related group (DRG) ( Table 1) . For example, if a discharge met the PAD diagnosis code criteria, but the stay was cate-gorized under the cardiac arrest DRG, we did not attribute the cost of that hospital stay to PAD. Similarly, the outpatient definition of PAD only considered services that were directly attributed to a diagnosis of PAD and excluded services that would usually not be identified as directly PAD-related (e.g. performance of chest X-rays and general biochemical or hematological testing). This algorithm is conservative in its estimate of PAD-related health care expenditures. Co-morbid conditions and risk factors were defined by their associated treatment codes, but smoking was not evaluated as a risk factor in this study because smoking is not reliably coded in the claims data. 12 In addition to the analysis conducted for this paper, this algorithm can be used to identify PAD patients to study a range of questions related to the disease. For example, the literature suggests that both primary cancer and associated treatment (e.g. chemotherapy regimens) may be associated with increased risk of both thrombotic and some peripheral arterial diseases. [13] [14] [15] [16] [17] The current algorithm can be used to identify PAD patients in any high-risk population (e.g. cancer patients undergoing chemotherapy) from claims data to enable the analysis of the impact of related medical interventions on PAD incidence or outcomes. Hence, we developed an algorithm for identifying PAD and quantifying its associated costs in a non-cancer population to permit its application to cancer populations to confirm or quantify this association.
Data analysis
We compared demographic characteristics between those treated for PAD in 2001 and those not treated for PAD in 2001. Statistical significance was assessed using the chi-square test for categorical variables and the Student's t-test for continuous normally distributed variables. We calculated mean and median costs of PAD treatment by treatment setting (inpatient and outpatient) and by whether the costs are absorbed by the Medicare program or by patients and their co-insurance (i.e. Medicare and non-Medicare). We weighted cost estimates based to the 2001 Medicare enrollment to produce national estimates. We separated inpatient PAD costs by DRG type and common surgical procedures.
Results
In the Medicare population, 10,370 of 152,381 (6.8%) beneficiaries in the sample were treated for PAD ( Table 2 ). Beneficiaries treated for PAD were slightly older (average, 79.5 years) than those who did not receive treatment for PAD (average, 76.3 years) (p = 0.0001). PAD patients were also more likely to be female (61.4% vs 59.7%, p = 0.001) and black (11% vs 6.9%, p = 0.001).
Patients treated for PAD were also considerably more likely to be treated for some atherosclerosis risk factors, such as hypertension and diabetes, but not others such as hyperlipidemia (Table 3) . Beneficiaries with PAD were more likely to have a diagnosis of acute myocardial infarction, stable and unstable angina, and congestive heart failure, as well as stroke and transient ischemic attack (p = 0.001).
Costs of PAD
Estimated outpatient, inpatient, and total PAD expenditures are presented in Table 4 . The mean annual per patient expenditure for PAD treatments was $1868 (± $111). Medicare's share of these payments comprise the majority of the expenditures. For the elderly individuals with PAD, Medicare spent an average of $1653 (± $107) on treatments for the condition. The majority of Medicare expenditures, $1450 (± $106) (88%), were the consequence of inpatient services. These figures, derived from the While inpatient care is the largest category of Medicare PAD expenditures, only 6.4% (n = 668) of PAD patients were admitted for a PAD-related hospitalization in 2001. Despite this small percentage, the majority of PAD admissions (63%) involved surgical care and, thus, PAD-related hospitalizations accounted for 88% of all Medicare PAD expenditures.
The three most commonly performed procedures were peripheral vascular shunt or bypass (n = 146, 1.4% of the PAD treated cohort, 22% of patients hospitalized for PAD), angioplasty of noncoronary vessels (n = 75, 0.7% of the PAD treated cohort, 11% of patients hospitalized for PAD), and above-knee amputations (n = 63, 0.6% of the PAD treated cohort, 9% of patients hospitalized for PAD). Total reimbursements for patients who undergo these procedures accounted for 16%, 7.8%, and 9.7% of total 2001 Medicare PAD expenditures, respectively.
Discussion
The US national health care expenditures for cardiovascular disease (coronary heart disease, stroke, and PAD) account for a large and increasing fraction of total US health care costs. 18 Inasmuch as the a The fraction of the PAD cohort with each co-morbidity was determined by searching inpatient, outpatient, and carrier files. A beneficiary was considered to have a given co-morbid condition if the diagnosis was coded in at least one hospital admission, and/or in at least two outpatient visits. b Percentages for co-morbid conditions do not total 100%, as some patients had multiple co-morbid conditions. Note that 48.6% of the beneficiaries treated for PAD and 76.1% of the beneficiaries not treated for PAD had none of the listed co-morbid conditions. Table 28 ). 19 We offer a conservative estimate of the health care costs of PAD to Medicare. First, beneficiaries with PAD are significantly more costly to the Medicare program than the typical Medicare elderly beneficiary. Mean Medicare expenditures for the PAD cases was $13,901, more than double the average Medicare expenditure ($5833) for an elderly enrollee. 19 Second, 'PAD-specific' treatments comprise a modest fraction of total Medicare expenditures for our PAD cases. Direct PAD-related treatment accounted for only 12% of total Medicare expenditures for these beneficiaries. That is, consistent with the results presented in Table 3 , elderly individuals with PAD have multiple comorbidities that are expensive to treat. We note that distinguishing PAD-specific treatment (e.g. lower extremity revascularization and amputation) from risk factors and cardiovascular disease (coronary and stroke) treatments is an artificial and semantical distinction, as atherosclerotic syndromes are co-prevalent. Thus, although Medicare enrollees with PAD (and their insurers and health systems) might consider their initial primary diagnosed 'cardiovascular disease' to be myocardial infarction or stroke, such events in these persons could be attributed to the antecedent undiagnosed PAD syndrome.
It is worthwhile to compare the characteristics of our Medicare-defined PAD cohort with cohorts derived from other epidemiologic studies. The 6.8% prevalence of PAD treatment in our cohort is consistent with previous studies that evaluated individuals aged 65 or older. 6, 20, 21 Our data demonstrate that treatment increased with age at rates of 4.5%, 7.5%, and 11.8% for individuals 65--74, 75-84, and >85 years, respectively. In contrast, the known population prevalence of PAD at these age strata are 12%, 20%, and at least 33%. 6, 22 Thus, only approximately one-third of the population with such estimated PAD had detectable PAD-related health care costs in our analysis. As for any such analysis, there are no methods that can be used to determine whether this 'undertreatment' is due to the non-diagnosis of PAD or due to other barriers to initiating any therapeutic option.
While our estimate of PAD costs is limited to costs directly attributed to PAD and may miss some PADrelated care, our case definition of PAD reproduces the established age-dependent prevalence increase documented from the NHANES population-based survey. 22 Finally, the PAD-treated beneficiaries had a higher prevalence of cardiovascular disease risk factors and comorbidities than the non-PAD treated cohort, which is consistent with previously published data. 5, 23, 24 Such increased co-prevalence underlies the observation that the mean Medicare expenditures for PAD-treated elders were more than double the average expenditure of a typical age eligible beneficiary (Table 4 ).
Only one US study has evaluated the health care resources and costs attributable to PAD. Margolis, et al. combined the data from two managed care organizations based in the southeastern and western US and reported the total average annualized cost of PAD-related care to be $5955 per patient. 11 These costs included the patient's co-payments, deductibles, coinsurances, drug costs, and hospitalizations for the PAD-related outcomes of myocardial infarction, stroke, transient ischemic attack, and amputations. These PAD-related hospitalizations accounted for 75% of the total PAD-related cost. Of the patients who had PAD-related surgical procedures (lower extremity vascular surgical bypasses, angioplasty, atherectomy, embolectomy, and stents), the annualized cost averaged $729 per PAD patient. The mean PAD-related surgical cost per patient ($1104) in our study is approximately 33% higher than the previously reported estimate. This difference is likely explained by the fact that our population was older (mean age 79.5 years vs 70.7 years) and that we limited our definition of 'surgical' patients to those who received their procedures in an inpatient setting. Finally, we note that only 15% of Medicare beneficiaries are enrolled in a health maintenance organization (HMO) and therefore it cannot be known whether the Margolis data can be extrapolated to the broader Medicare population. Yet, the Margolis study, a Canadian study 25 and our work all find the majority of PAD-related costs to be for inpatient surgical care. We note that the surgical and endovascular procedures are utilized to diminish amputation and improve quality of life in individuals with advanced clinical stages of PAD. The costs associated with use of these hospital-based invasive PAD care strategies are valuable, improve clinical outcomes, and thus diminish suffering for these Medicare enrollees.
In the context of the high costs derived from procedures performed in the inpatient setting, it seems that outpatient preventive strategies (i.e. risk factor modification to avoid PAD progression, use of antiplatelet medications to decrease myocardial infarction and stroke, and exercise and medications to improve claudication) might be more costeffective. There are few clinical trials that have investigated the impact of risk factor modification specifically for PAD, but the current clinical trials database has suggested consistent benefits. 5 For example, in the Scandinavian Simvastatin Survival Study (4S), individuals with coronary heart disease treated with simvastatin (20-40 mg/day) had a 38% lower risk of new or worsening intermittent claudication compared with those on placebo. 26 In the Heart Protection Study, treatment with simvastatin (40 mg/day) decreased the composite risk of myocardial infarction, stroke, vascular death, and revascularization procedures by 20%, a benefit that was observed in individuals enrolled on the basis of PAD. 27 Individuals with diabetes undergo hospital admission due to PAD, associated infections, and skin ulceration, which are preventable complications of this disease. 28 A meta-analysis has demonstrated that a structured exercise program with duration greater than 30 minutes per session, three sessions per week was associated with a major improvement in maximal walking time for patients with PAD. 29 To date, there have been no randomized clinical trials that prospectively investigate the benefits of smoking cessation and weight loss in patients with PAD. Because cardiovascular disease and PAD share a common pathophysiology, it is reasonable to assume that smoking cessation and weight loss, which have been shown to reduce the risk of coronary heart disease and its associated morbid and expensive ischemic events, might also beneficially decrease progression of PAD. 30, 31 Future research is needed to determine how much cost savings might be derived from cardiovascular disease risk factor modifications in the PAD population.
Study limitations
Although this investigation demonstrates a high cost of PAD care, our study is not without limita-tions. First, all health care expenditure estimates rely on the accuracy of the coding of the Medicare data and the accurate use of these codes. Second, although Medicare data are a good source of expenditure data, our study does not capture services such as drugs, durable medical equipment, and outpatient rehabilitation. Third, while we believe that we have developed a definition of lower extremity PAD that differentiates PAD-related care and its costs, such definitions may be alternatively defined. We note that the definition of PAD care used in our study is very similar to that used by Margolis, et al. 11 
Conclusion
The cost of PAD-related care in the Medicare population is substantial. The average Medicare expenditures related to PAD were $1653 per patient in 2001. It is important to note that most of these costs were incurred in the inpatient setting to treat severe manifestations of limb ischemia. As recognition of PAD increases, the health care expenditures associated with this common atherosclerotic syndrome may increase. Alternatively, earlier recognition of PAD by patients and clinicians should offer an opportunity to reduce costs via initiation of preventive care strategies. Earlier use of preventive care (e.g. atherosclerosis risk reduction), outpatient claudication treatments (e.g. supervised exercise), and durable revascularization interventions should be evaluated as strategies to both improve health and limit national health care costs.
